EQUITY SECURITIES PORTFOLIO INVESTMENT (Tables)

3 Months Ended

Mar. 31, 2025

Investments, Debt and Equity Securities [Abstract]

Unrealized Gain (Loss) on Investments

Equity securities for the periods presented were comprised of the following:

Security Type	Cost		Gross Unrealized Gain		Gross Unrealized Loss		Fair Value
	(In thousands)
March 31, 2025:
Equity securities - other common stock	$	24,605	$	20	$	(6,561)	$	18,064
Total	$	24,605	$	20	$	(6,561)	$	18,064
December 31, 2024:
Equity securities - other common stock	$	24,898	$	118	$	(1,881)	$	23,135
Total	$	24,898	$	118	$	(1,881)	$	23,135

The following unrealized and realized gains or losses from our investment in the Life Sciences Portfolio are recorded in the change in fair value of equity securities and gain or loss on sale of equity securities, respectively, in the condensed consolidated statements of operations and comprehensive income (loss):

	Three Months Ended March 31,
	2025		2024
	(In thousands)
Change in fair value of equity securities of public    companies	$	—	$	(28,581)
Gain on sale of equity securities of public    companies	—		28,581
Net realized and unrealized gain	$	—	$	—